Programs - Axcess Technology

Licensee Programmes

PRODUCT

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

Diabetology Oral Programs: Clinical Progress

Capsulin™ Oral Insulin OAD*

Preparing for Phase 3

Capsulin™ Oral Insulin IR**

12-week study in completion

Oraglutide™ Oral Weekly GLP1 RA

12-week study commenced

Satietyde™: Microdosing Daily Oraglutide for Dropouts and Maintenance Therapy

Preparing for Phase 2 based on Oraglutide data

Oral Fusion GIP/GLP1 Once Weekly POC

IVGTT Human Proof of Concept study

Capsuglutide™: Capsulin™ / Oraglutide™ combination

Preparing for clinic

Capsulin™ / small molecule

Tested in animal models

Oral GLP-1 / GIP combination

Preparing for animal studies

Oral GLP-1 / Gut hormone combination

Preparing for animal studies

Oral Obesity Triagonist peptides

Preparing for animal studies

Potentional Oral Delivery of Third-party Therapeutics (API)

Oral delivery of marketed macromolecules

Oral delivery of development macromolecules

Potentional combination therapies

* OAD is Oral Anti Diabetic agent for treatment of T2DM – improves glycaemic control and compliance and reduces side effects

** IR is an Oral Insulin Replacement for treatment of T1DM – reduces insulinaemia and improves glycaemic control

PRODUCT

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

Axcess Internal Oral Programs: Clinical Progress

Oral Calcitonin

End of Phase 2

Oral Parathyroid Hormone

Phase 2A Completed

Oral Human Growth Hormone

Available for clinic

Oral C-Peptide

Available for clinic

Oral Antibody

In research

Insulin Resistance

Diagnosed diabetes cost the United States $412.9 billion in 2022, one in four health care dollars. Overweight and obesity are projected to cost the world $4.32 trillion a year by 2035, about 3% of global GDP. Dementia already costs more than $1.3 trillion a year worldwide.

Capsulin ™ - Oral Insulin

Treatment of Type 2 diabetes mellitus

Oraglutide ™ - Oral GLP-1

Treatment of Type 2 diabetes and obesity

Diabetes Epidemic

12-13% of global adult population (OECD)

Obesity

6% of global population (OECD)

Osteoporosis

1 in 3 women & 1 in 12 men over 50 have osteoporosis

Licensee Programmes

Diabetology Oral Programs: Clinical Progress

Potentional Oral Delivery of Third-party Therapeutics (API)

Axcess Internal Oral Programs: Clinical Progress

Insulin Resistance

Capsulin ™ - Oral Insulin

Oraglutide ™ - Oral GLP-1

Diabetes Epidemic

Obesity

Osteoporosis

HEADQUARTERS:
Charter Place,
23/27 Seaton place,
St Helier,
Jersey JE1 1JY,
Channel Islands

AXCESS LABORATORY:
The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH
United Kingdom

Licensee Programmes

Diabetology Oral Programs: Clinical Progress

Potentional Oral Delivery of Third-party Therapeutics (API)

Axcess Internal Oral Programs: Clinical Progress

Insulin Resistance

Capsulin ™ - Oral Insulin

Oraglutide ™ - Oral GLP-1

Diabetes Epidemic

Obesity

Osteoporosis

Subscribe to our newsletter